BeStock  
Stocks › Biotechnology › SRPT

Sarepta Therapeutics SRPT

US equityMarket cap rank #2908Biotechnology
$13.33 −$0.84 (-5.93%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $13.60 +2.03%
Open$13.92
Prev close$14.17
Day range$13.25 – $14.47
Volume2.25M
Market cap$1.43B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$381.35M-4.5% YoY
Operating profit-$9.04M+85.6% YoY
Net profit-$28.46M+43.7% YoY
Diluted EPS-$0.27+46.0% YoY
Free cash flow$53.83M+226.4% YoY
Operating cash flow$59.97M

Revenue, last 8 quarters

$658.4MDec '24$744.9MMar '25$611.1MJun '25$399.4MSep '25$442.9MDec '25$730.8MMar '26$401.3MJun '26$381.4MSep '26

Net profit, last 8 quarters

$159.0MDec '24$-447.5MMar '25$196.9MJun '25$-50.6MSep '25$-412.2MDec '25$331.0MMar '26$-4.9MJun '26$-28.5MSep '26

Diluted EPS by quarter

1.50Dec '24-4.60Mar '251.89Jun '25-0.50Sep '25-3.93Dec '252.88Mar '26-0.05Jun '26-0.27Sep '26

Free cash flow by quarter

$54.0MDec '24$-629.3MMar '25$229.8MJun '25$-42.6MSep '25$126.8MDec '25$-205.8MMar '26$196.5MJun '26$53.8MSep '26

Annual revenue

$540.1MFY20$701.9MFY21$933.0MFY22$1.2BFY23$1.9BFY24$2.2BFY25

Profitability & balance sheet

Gross margin56.8%
Operating margin-0.4%
Net margin-5.9%
Return on equity-8.0%
Return on assets-3.4%
Return on invested capital-3.1%
Current ratio3.46
Liabilities / assets51.7%
Cash & investments$878.78M
Total debt$1.05B
Net cash (debt)-$174.25M
Free cash flow / sales8.8%

Where the revenue comes from

Quarter 2026/Q3

By business line

  • Phosphorodiamidate morpholino oligomer (PMO) product revenues, net$240.31M 63.0%
  • ELEVIDYS product revenues, net$83.45M 21.9%
  • Collaboration and other$57.59M 15.1%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $381.35M $401.25M $730.80M $2.20B $442.93M
Total Operating Revenue $381.35M $401.25M $730.80M $2.20B $442.93M
Cost of Revenue $188.51M $149.39M $108.77M $839.61M $398.71M
Gross Profit $192.84M $251.87M $622.04M $1.36B $44.23M
Operating Expense $201.88M $199.58M $263.60M $2.02B $454.31M
Selling and Admin Expenses $118.61M $107.60M $108.95M $491.72M $128.30M
-General & Admin Expense $118.61M $107.60M $108.95M $491.72M $128.30M
Research & Development $82.55M $91.26M $153.96M $1.52B $325.34M
Depreciation & Amortization & Depletion $718,000.00 $717,000.00 $691,000.00 $2.62M $677,000.00
-Depreciation & Amortization $718,000.00 $717,000.00 $691,000.00 $2.62M $677,000.00
Operating Profit -$9.04M $52.29M $358.43M -$657.77M -$410.08M
Net Non-Operating Interest Income (Expense) -$13.41M -$14.35M -$14.71M -$1.45M -$10.21M
Non-Operating Interest Income $8.20M $7.16M $7.00M $36.69M $8.74M
Non-Operating Interest Expense $21.62M $21.51M $21.71M $38.14M $18.95M
Other Income (Expense) -$3.31M -$39.69M -$548,000.00 -$43.00M $12.62M
Gain on Sale of Security -$523,000.00 -$448,000.00 -$1.71M -$15.91M $1.35M
Special Income (Charges) $0.00 -$39.00M – -$25.15M $11.60M
-Less:Restructuring and Mergern & Acquisition $0.00 – – $42.01M $1.50M
Other Non-Operating Income (Expenses) -$2.79M -$246,000.00 $1.16M -$1.94M -$338,000.00
Pretax Profit -$25.77M -$1.75M $343.17M -$702.23M -$407.68M
Tax $2.70M $3.14M $12.22M $11.19M $4.55M
Net Profit -$28.46M -$4.89M $330.96M -$713.41M -$412.23M
Profit from Continuing Operations -$28.46M -$4.89M $330.96M -$713.41M -$412.23M
Net Income to Parent Company -$28.46M -$4.89M $330.96M -$713.41M -$412.23M
Net Income to Common Stockholders -$28.46M -$4.89M $330.96M -$713.41M -$412.23M
Basic EPS -$0.27 -$0.05 $3.15 -$7.13 -$3.93
Diluted EPS -$0.27 -$0.05 $2.88 -$7.13 -$3.93
-Less:Other Special Charges – $39.00M – -$16.86M -$13.10M
-Less:Write Off – – – $0.00 –

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $3.17B $3.19B $3.18B $3.35B $3.35B
Total Current Assets $2.27B $2.22B $2.31B $2.54B $2.54B
Cash and Cash Equivalents & Short-Term Investments $878.78M $788.49M $653.19M $939.65M $939.65M
-Cash and Cash Equivalents $472.76M $571.15M $464.45M $801.28M $801.28M
-Short Term Investments $406.02M $217.34M $188.74M $138.37M $138.37M
Receivables $427.48M $438.81M $547.91M $519.61M $519.61M
-Accounts Receivable $369.18M $376.82M $394.82M $398.23M $398.23M
-Accrued Interest Receivable $2.99M $3.49M $2.62M $1.66M $1.66M
-Taxes Receivable $13.81M $13.49M $14.03M $15.60M $15.60M
-Other Receivables $41.50M $45.02M $136.45M $104.12M $104.12M
Prepaid Assets $85.56M $77.50M $102.44M $154.73M $154.73M
Inventory $876.12M $904.27M $1.00B $914.74M $914.74M
Other Current Assets $4.95M $14.75M $5.23M $9.20M $9.20M
Total Non-Current Assets $893.18M $964.69M $869.06M $811.77M $811.77M
Net PPE $437.00M $446.84M $460.30M $470.62M $470.62M
-Gross PPE $437.00M $446.84M $460.30M $751.54M $751.54M
Investments and Advances $114.64M $151.72M $89.73M $10.57M $10.57M
Non-Current Prepaid Assets $93.82M $91.03M $92.73M $95.95M $95.95M
Goodwill and Other Intangible Assets $29.83M $30.61M $31.38M $28.95M $28.95M
Non-Current Deferred Assets $2.85M $2.86M $2.81M $2.82M $2.82M
Other Non-Current Assets $215.04M $241.62M $192.11M $202.86M $202.86M
Total Liabilities $1.64B $1.66B $1.67B $2.21B $2.21B
Total Current Liabilities $656.35M $502.91M $499.16M $1.10B $1.10B
Payables $55.92M $60.29M $84.17M $285.60M $285.60M
-Accounts Payable $45.70M $50.98M $70.38M $280.84M $280.84M
-Total Tax Payable $10.22M $9.31M $13.79M $4.76M $4.76M
Current Accrued Expenses $156.64M $156.31M $141.42M $178.78M $178.78M
Short-Term Debt and Capital Lease Obligation $157.97M – – $11.39M $11.39M
-Current Debt $157.97M – – – –
Current Provisions $109.10M $118.64M $114.29M $117.52M $117.52M
Current Deferred Liabilities $104.89M $110.13M $116.04M $443.40M $443.40M
Other Current Liabilities $26.03M $16.56M $10.38M – –
Total Non-Current Liabilities $980.86M $1.16B $1.17B $1.11B $1.11B
Long Term Debt and Capital Lease Obligation $895.06M $1.05B $1.04B $1.03B $1.03B
-Long Term Debt $699.39M $847.62M $838.16M $828.97M $828.97M
-Long Term Capital Lease Obligation $195.66M $198.23M $198.51M $199.38M $199.38M
Non-Current Deferred Liabilities $83.91M $110.13M $136.35M $83.91M $83.91M
Other Non-Current Liabilities $1.89M $1.83M $1.65M $1.53M $1.53M
Total Equity $1.53B $1.53B $1.51B $1.14B $1.14B
Stockholders' Equity $1.53B $1.53B $1.51B $1.14B $1.14B
Capital Stock $11,000.00 $11,000.00 $11,000.00 $11,000.00 $11,000.00
-Common Stock $11,000.00 $11,000.00 $11,000.00 $11,000.00 $11,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $6.13B $6.10B $6.08B $6.04B $6.04B
Retained Earnings -$4.58B -$4.55B -$4.55B -$4.88B -$4.88B
Less: Treasury Stock -$25.01M -$25.26M -$25.26M -$25.26M -$25.26M
Gains/Losses Not Affecting Retained Earnings -$1.59M -$565,000.00 -$121,000.00 $272,000.00 $272,000.00
-Accumulated Depreciation – – – -$280.92M -$280.92M
-Other Intangible Assets – – – $28.95M $28.95M
-Current Capital Lease Obligation – – – $11.39M $11.39M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $59.97M $197.07M -$202.68M -$205.48M $131.21M
Net cash flow from continuing operations $59.97M $197.07M -$202.68M -$205.48M $131.21M
Net Income from Continuing Operations -$28.46M -$4.89M $330.96M -$713.41M -$412.23M
Gain/Loss from Continuing Operations $3.82M $3.66M $4.82M $14.38M -$10.45M
Depreciation & Depletion & Amortization $5.90M $10.41M $10.59M $44.52M $5.25M
Other Non-Cash Items $12.60M $9.38M $8.32M $70.59M $14.23M
Change in Working Capital $40.40M $143.34M -$586.25M $78.04M $339.51M
-Change in Receivables $7.65M $17.99M $3.42M $203.76M -$2.49M
-Change in Inventory $59.64M $39.91M -$69.76M -$301.09M $18.48M
-Change in Prepaid Assets -$15.90M $25.79M $43.49M $78.84M $11.77M
-Change in Payables and Accrued Expense $3.80M $3.30M -$270.49M $104.27M $249.62M
-Change in Other Current Assets $19.32M $82.39M -$14.55M -$79.78M $20.29M
-Change In Other Working Capital -$31.47M -$32.13M -$274.92M $72.05M $41.86M
Net cash flow from investing -$158.35M -$93.37M -$134.39M $69.64M $96.21M
Net Cash Flow from Continuing Investing Activities -$158.35M -$93.37M -$134.39M $69.64M $96.21M
Net PPE Purchase and Sale -$2.93M -$555,000.00 -$2.08M -$101.97M -$3.59M
Net Intangibles Purchase and Sale -$3.20M $0.00 -$1.00M -$7.88M -$796,000.00
Net Investment Purchase and Sale -$152.22M -$92.82M -$131.31M $5.39M $100.59M
Financing Cash Flow $0.00 $0.00 $241,000.00 -$168.34M -$39.21M
Net Cash Flow from Continuing Financing Activities $0.00 $0.00 $241,000.00 -$168.34M -$39.21M
Net Issuance Payments Of Debt $0.00 $0.00 $0.00 -$162.59M -$39.26M
Net Common Stock Issuance $0.00 – – -$5.01M $0.00
Proceeds from Stock Option Exercised $0.00 $0.00 $241,000.00 $18.70M $308,000.00
Ending Cash Balance $482.89M $581.27M $477.58M $814.41M $814.41M
Net Change in Cash -$98.39M $103.70M -$336.83M -$304.18M $188.21M
Beginning Cash Balance $581.27M $477.58M $814.41M $1.12B $626.20M
Free Cash Flow $53.83M $196.52M -$205.76M -$315.33M $126.82M
-Change in Other Current Liabilities – $6.08M -$3.44M – –
Net Business Purchase and Sale – – $0.00 $174.10M $0.00
Net Other Financing Charges – – – -$19.45M -$261,000.00

Discussion

No comments yet — be the first to weigh in on SRPT.

Sign in to join the discussion.

Scroll to Top